Controlled document PF-009A
PLEXUS BRACHIALIS Phase 1 Master Formula
TemplateDocumented
Record identification
- Document ID
- PF-009A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-009A
PRODUCT FORMULA CARD
SIRIAM PLEXUS BRACHIALIS DUO – PHASE 1 (NERVE RELEASE)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PB-001 |
| MF-009 |
| PF-009A |
| PLEXUS BRACHIALIS DUO – Phase 1 |
| C5–C8 / T1 |
| Nerve Release |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
ValueSIR-PB-001
ValueMF-009
ValuePF-009A
ValuePLEXUS BRACHIALIS DUO – Phase 1
ValueC5–C8 / T1
ValueNerve Release
ValueTopical Magistral Cream
Value100 g
Value2.0
Value🔒 LOCKED
Value☐
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurodermal modulation of the brachial plexus and peripheral afferent input |
| C5–C8 / T1 |
| Peripheral neurogenic unloading and neuro-inflammatory modulation |
| Phase 1 – Nerve Release |
| Topical Magistral Cream |
DescriptionNeurodermal modulation of the brachial plexus and peripheral afferent input
DescriptionC5–C8 / T1
DescriptionPeripheral neurogenic unloading and neuro-inflammatory modulation
DescriptionPhase 1 – Nerve Release
DescriptionTopical Magistral Cream
2. MASTER FORMULA
The ingredient quantities follow the magistral fiche, with the agreed SQMS standardisation for Vitamin E and Silicea.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 65.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 18.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 3.00 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 2.50 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| Vitals |
| 2.00 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| WeightWorld |
| 1.00 |
| g |
| L |
| BE-010 |
| Hypericum perforatum D6 |
| — |
| 0.50 |
| mL |
| C |
| BE-003 |
| Ginkgo biloba |
| Mattisson |
| 0.80 |
| g |
| C |
| BE-009 |
| Ruta graveolens |
| — |
| 0.30 |
| mL |
| C |
| BE-008 |
| Arnica montana D6 |
| — |
| 0.50 |
| mL |
| C |
| BE-002 |
| Copaiba Oil |
| Aroma-Zone |
| 0.30 |
| mL |
| C |
| AC-006 |
| α-Bisabolol |
| — |
| 0.20 |
| g |
| L |
| AC-002 |
| Betaine (TMG) |
| — |
| 0.50 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| Natural Heroes |
| 0.50 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.50 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 2.00 |
| g |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
CodeOfficial Ingredient
CodeSupplier
CodeMaster Qty
CodeUnit
CodePhase
CodePC-001
CodeLanette Cream FNA
CodeFagron
Code65.00
Codeg
CodeB
CodePC-002
CodeAqua Purificata
CodeFagron
Code18.00
Codeg
CodeW
CodeSC-001
CodeMagnesium Chloride
CodeFagron
Code3.00
Codeg
CodeW
CodeSC-002
CodeMSM
Code—
Code2.50
Codeg
CodeW
CodeAC-003
CodePalmitoylethanolamide (PEA)
CodeVitals
Code2.00
Codeg
CodeD
CodeBE-001
CodeBoswellia serrata
CodeWeightWorld
Code1.00
Codeg
CodeL
CodeBE-010
CodeHypericum perforatum D6
Code—
Code0.50
CodemL
CodeC
CodeBE-003
CodeGinkgo biloba
CodeMattisson
Code0.80
Codeg
CodeC
CodeBE-009
CodeRuta graveolens
Code—
Code0.30
CodemL
CodeC
CodeBE-008
CodeArnica montana D6
Code—
Code0.50
CodemL
CodeC
CodeBE-002
CodeCopaiba Oil
CodeAroma-Zone
Code0.30
CodemL
CodeC
CodeAC-006
Codeα-Bisabolol
Code—
Code0.20
Codeg
CodeL
CodeAC-002
CodeBetaine (TMG)
Code—
Code0.50
Codeg
CodeW
CodeSC-003
CodeD-Panthenol
CodeNatural Heroes
Code0.50
Codeg
CodeW
CodeSC-004
CodeVitamin E Full Spectrum
CodeNatural Heroes
Code0.50
Codeg
CodeL
CodeSC-005
CodeSilicea Gel (+1 drop Silicea D8)
Code—
Code2.00
Codeg
CodeC
CodePR-001
CodeCosgard 221
CodeAromantic
Code0.70
Codeg
CodeC
3. MANUFACTURING WORKFLOW
Step
1
2
3
4
5
6
7
8
9
10
11
Based on the Lanette preparation protocol in the source document.
| Action |
|---|
| ✓ |
| Verify raw materials |
| □ |
| Prepare water phase |
| □ |
| Dissolve Magnesium Chloride and MSM |
| □ |
| Prepare PEA/Boswellia dispersion |
| □ |
| Emulsification |
| □ |
| Cool below 40°C |
| □ |
| Add thermolabile ingredients |
| □ |
| Add Silicea Gel (+1 drop Silicea D8) |
| □ |
| Quality Control |
| □ |
| Fill into airless dispensers |
| □ |
| Batch Release |
| □ |
Action✓
ActionVerify raw materials
Action□
ActionPrepare water phase
Action□
ActionDissolve Magnesium Chloride and MSM
Action□
ActionPrepare PEA/Boswellia dispersion
Action□
ActionEmulsification
Action□
ActionCool below 40°C
Action□
ActionAdd thermolabile ingredients
Action□
ActionAdd Silicea Gel (+1 drop Silicea D8)
Action□
ActionQuality Control
Action□
ActionFill into airless dispensers
Action□
ActionBatch Release
Action□
4. QUALITY CONTROL
Parameter
Appearance
Colour
Odour
Homogeneity
pH
Viscosity
Packaging
Net Weight
| Target |
|---|
| Result |
| Standard |
| Standard |
| Standard |
| Pass |
| 5.2–5.5 |
| Airless compatible |
| Pass |
| Pass |
TargetResult
TargetStandard
TargetStandard
TargetStandard
TargetPass
Target5.2–5.5
TargetAirless compatible
TargetPass
TargetPass
5. BATCH RELEASE
Field
Batch Number
Production Date
Yield
Prepared by
Checked by
Released by
| Value |
|---|
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Peripheral Pathways
Frequency
Treatment Phase
Application zones and EMG objectives are defined in the magistral fiche.
| Value |
|---|
| C5–C8 / T1 |
| Supraclavicular |
| Infraclavicular |
| Axillary region |
| Radial, Median and Ulnar nerve trajectories |
| 1–2× daily |
| Weeks 1–2 |
ValueC5–C8 / T1
ValueSupraclavicular
ValueInfraclavicular
ValueAxillary region
ValueRadial, Median and Ulnar nerve trajectories
Value1–2× daily
ValueWeeks 1–2
Related documents
Platform modules